NCT05873686View on ClinicalTrials.gov

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

PHASE1RecruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

October 26, 2023

Primary Completion Date

March 31, 2027

Study Completion Date

July 31, 2027

Conditions
Advanced Solid TumorNSCLC (Non-small Cell Lung Cancer)Renal CancerMesotheliomaNon-Small Cell Squamous Lung CancerNon-small Cell Lung Adenocarcinoma
Interventions
DRUG

NXP900

NXP900 is an orally administered SRC/YES1 kinase inhibitor

Trial Locations (7)

32224

RECRUITING

Mayo Clinic, Jacksonville

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

80218

RECRUITING

Sarah Cannon Research Institute at HealthONE, Denver

85054

RECRUITING

Mayo Clinic, Phoenix

97239

RECRUITING

Oregon Health and Science University, Portland

EH4 2XU

COMPLETED

Western General Hospital - NHS Lothian, Edinburgh

SW3 6JJ

COMPLETED

The Royal Marsden NHS Foundation and Trust, London

Sponsors
All Listed Sponsors
lead

Nuvectis Pharma, Inc.

INDUSTRY

NCT05873686 - A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers | Biotech Hunter | Biotech Hunter